BioSpace News Archive

Bone Solutions Inc. (BSI), an orthobiologics technology company located in Colleyville, Texas, announced today the immediate commercial launch of Mg OSTEOINJECT, the first injectable bone void filler in the U.S. to incorporate magnesium - a critical component for bone health and development.

Gritstone bio, Inc. announced that the company’s Board of Directors has granted eleven employees nonqualified stock options to purchase an aggregate of 63,400 shares of its common stock with an exercise price of $6.30, which is equal to the closing price of Gritstone’s common stock on January 13, 2022, the grant date of the awards.

Sierra Oncology, Inc., a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, announced that it intends to offer and sell $100.0 million of shares of its common stock in an underwritten public offering.

The global pharma & healthcare market report points out the key trends and developments taking place in this business space in the ongoing COVID-19 times.

Advanced analytical tools such as SWOT analysis and Porter’s Five Forces analysis along with details diagrams, graphs, and figures have been applied in this study.

Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat hosted by Justin Walsh, Equity Research Analyst (Biotechnology), at the B. Riley Securities’ Virtual Oncology Conference.

Avivagen Inc. is excited to announce the appointment of James (“Jamie”) Nickerson, PhD as President of Avivagen.

Merus N.V. today announced the appointment of Shannon Campbell as Executive Vice President & Chief Commercial Officer.

Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, will host a live video webcast of its Investor R&D Day on Friday, January 28, 2022.

Vaccination against COVID-19 did not affect fertility outcomes in patients undergoing in-vitro fertilization (IVF), a new study has found.